How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Buy
56
MLAB Quote, Financials, Valuation and Earnings
Last price:
$118.89
Seasonality move
:
9.75%
Day range:
$114.67 - $119.90
52-week range:
$83.68 - $155.12
Dividend yield:
0.54%
P/E ratio:
--
P/S ratio:
2.73x
P/B ratio:
4.19x
Volume:
63.4K
Avg. volume:
40.3K
1-year change:
8.97%
Market cap:
$649.7M
Revenue:
$216.2M
EPS (TTM):
-$46.26
Analysts' Opinion
-
Consensus RatingMesa Laboratories has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $150.00, Mesa Laboratories has an estimated upside of 25.45% from its current price of $119.57.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $120.00 representing 100% downside risk from its current price of $119.57.
Fair Value
-
According to the consensus of 4 analysts, Mesa Laboratories has 25.45% upside to fair value with a price target of $150.00 per share.
MLAB vs. S&P 500
-
Over the past 5 trading days, Mesa Laboratories has underperformed the S&P 500 by -2.97% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Mesa Laboratories does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Mesa Laboratories has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Mesa Laboratories reported revenues of $62.8M.
Earnings Growth
-
Mesa Laboratories has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Mesa Laboratories reported earnings per share of -$0.31.
Enterprise value:
814.5M
EV / Invested capital:
--
Price / LTM sales:
2.73x
EV / EBIT:
--
EV / Revenue:
3.43x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
18.94x
Price / Operating cash flow:
15.10x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$149M
Return On Assets:
-49.49%
Net Income Margin (TTM):
-104.92%
Return On Equity:
-122.79%
Return On Invested Capital:
-59.87%
Operating Margin:
9.2%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $222.4M | $212.9M | $237.7M | $53.5M | $62.8M | |
| Gross Profit | $135.6M | $129.9M | $149M | $33.4M | $39.8M | |
| Operating Income | $2.7M | -$274K | $18.1M | -$67K | $5.8M | |
| EBITDA | $38.6M | $38.2M | -$235.9M | $12.9M | $6.1M | |
| Diluted EPS | -$0.29 | $0.17 | -$46.26 | $0.39 | -$0.31 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $295.3M | $121M | $114.2M | $118.4M | $110.8M | |
| Total Assets | $621.6M | $721.7M | $663M | $741.8M | $437.1M | |
| Current Liabilities | $27.8M | $46.8M | $41.6M | $44.2M | $155.9M | |
| Total Liabilities | $208.8M | $325.4M | $275.8M | $338.8M | $281.9M | |
| Total Equity | $412.8M | $396.3M | $387.2M | $403M | $155.2M | |
| Total Debt | $144.3M | $229.1M | $189M | $233M | $195.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $24.8M | $43.8M | $47M | $11.5M | $18.4M | |
| Cash From Investing | -$9.3M | -$82.8M | -$3.1M | -$80.8M | -$813K | |
| Cash From Financing | -$39M | $41.4M | -$41.2M | $60.8M | -$10.6M | |
| Free Cash Flow | $20.5M | $40.7M | $43M | $10.4M | $17.6M | |
MLAB
Sector
Market Cap
$649.7M
$36.4M
Price % of 52-Week High
77.08%
44.07%
Dividend Yield
0.54%
0%
Shareholder Yield
--
-1.03%
1-Year Price Total Return
8.97%
-41.85%
Beta (5-Year)
0.818
0.775
Dividend yield:
0.54%
Annualized payout:
$0.64
Payout ratio:
-1.39%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$124.11
200-day SMA
Sell
Level
$122.69
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$128.47
Relative Strength Index (RSI14)
Sell
Level
36.20
ADX Line
Neutral
Level
0
Williams %R
Buy
Level
-81.2789
50-day SMA
Sell
Level
$136.57
MACD (12, 26)
Sell
Level
-4.31
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.7319)
Sell
CA Score
(Annual)
Level (-2.5718)
Buy
Beneish M-Score
(Annual)
Level (-5.9713)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (3.9193)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.
Stock Forecast FAQ
In the current month, MLAB has received 2 Buy ratings 1 Hold ratings, and 1 Sell ratings. The MLAB average analyst price target in the past 3 months is $150.00.
-
Where Will Mesa Laboratories Stock Be In 1 Year?
According to analysts, the consensus estimate is that Mesa Laboratories share price will rise to $150.00 per share over the next 12 months.
-
What Do Analysts Say About Mesa Laboratories?
Analysts are divided on their view about Mesa Laboratories share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mesa Laboratories is a Sell and believe this share price will drop from its current level to $120.00.
-
What Is Mesa Laboratories's Price Target?
The price target for Mesa Laboratories over the next 1-year time period is forecast to be $150.00 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 1 rates the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is MLAB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Mesa Laboratories is a Buy. 2 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MLAB?
You can purchase shares of Mesa Laboratories via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mesa Laboratories shares.
-
What Is The Mesa Laboratories Share Price Today?
Mesa Laboratories was last trading at $118.89 per share. This represents the most recent stock quote for Mesa Laboratories. Yesterday, Mesa Laboratories closed at $119.57 per share.
-
How To Buy Mesa Laboratories Stock Online?
In order to purchase Mesa Laboratories stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Is JHX Stock a Buy Sell or Hold?
James Hardie Industries (NYSE:JHX) is a manufacturer of outside building…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
69
AJINY alert for Apr 1
Ajinomoto [AJINY] is down 2.15% over the past day.
Sell
40
RGC alert for Mar 31
Regencell Bioscience Holdings [RGC] is up 26.1% over the past day.
Buy
62
AGX alert for Apr 1
Argan [AGX] is down 4.98% over the past day.
